(24/7 MARKET NEWS) – Baudax Bio, Inc. (NASDAQ:BXRX) reported, this morning, the successful outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.
Baudax Bio is trading at $3.85, 71-cents higher (22.22%), on 1.4 million shares traded.
Its 52-week range is $1.55 to $306.46. It’s well off its 52-week high, but is about to eclipse its 2023 highs and its setup is favorable for a potential run.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.